A sensor that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing and an analyte indicator covering at least a portion of the sensor housing. The sensor may include a drug-eluting matrix that covers at least a portion of the analyte indicator. The drug-eluting matrix may include one or more openings configured to allow the medium to pass through the drug-eluting matrix and come into contact with the analyte indicator. The sensor may include one or more therapeutic agents. The one or more therapeutic agents may reduce deterioration of the analyte indicator. The one or more therapeutic agents may be incorporated within the drug-eluting matrix.

The present subject matter relates to light-activatable polymeric nanoparticles (NPs) for the transportation and release of an active substance, methods for obtain said particles and their uses. A light-activatable nanoparticle for the transportation and release of an active substance, comprising a polycation preferably a polimer polycation, a polyanion and a light-sensitive photochrome attached to the polycation or the polyanion, wherein said photochrome is hydrophobic and suitable to photo-cleave when activated by an irradiation source, generating a negative charge and releasing the active substance. Light-activatable. The disclosure subject matter shows that NPs are a highly efficient drug delivery system to primary leukemic cells based on opto-nanomedicine system. Therefore, the present disclosure is useful for remote control in the release of biomolecules with spatio-temporal resolution with applications in the areas of general therapeutic and regenerative medicine applications.

A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function.

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

A biodegradable electroactive material can be doped with a drug and the drug can be delivered to a living subject by stimulating the material with an electrical potential. The material (in this case a polymer) has an electrochemically responsive oligoaniline block terminated with a carboxylic acid moiety and is linked to an alcohol-terminated diol by an ester bond. Advantageously, the diol is PEG-400, PEG-2000, PCL-530, or PCL-2000.

The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses.

This disclosure relates to compositions and uses of caged proteins substituted with a photon decomposing chemical structure wherein the photon decomposing chemical structure is substituted through a linking group to a hydrophilic polymer. In certain embodiments, the caged protein is a proteinaceous agent such as an anticancer agent, cytokine, interleukin, fragment, or fusion thereof.

Synthetic liposomal nanoparticles comprising a cell-free transcription and translation machinery, a plasmid encoding a cytokine, and a regulatable caged ATP molecule, as well as microparticles encasing the synthetic liposomal nanoparticles and methods of making and using the synthetic liposomal nanoparticles, are described herein. These liposomal nanoparticles may be used for the controlled release o a cytokine within a localized environment of, for example a tumor, as part of a therapeutic treatment of cancer, or for localized treatment at a focus of interest of an autoimmune disease, an allergic reaction or hypersensitivity reaction, a localized site of an infection or infectious disease, a localized site of an injury or other damage, a transplant or other surgical site, or a blood clot. Further, microparticles produced by encapsulating hundreds of liposomal nanoparticles, and their therapeutic uses, are also described.